A pharmaceutical company has conducted a study to test the efficacy of a new anti-diabetic drug. The mean reduction in HbA1c levels recorded in the study population (n=100) was found to be 1.5 ± 0.3%. The 95% Confidence Interval (CI) for the mean reduction of HbA1c levels within this population was calculated to be (1.3%, 1.7%). What is the appropriate conclusion based on this interval?

A 75-year-old male patient with hypertension participates in a randomized controlled trial evaluating the efficacy of a new antihypertensive medication in reducing systolic blood pressure. The patient’s systolic blood pressure increases despite being compliant with the medication regimen and not reporting any adverse effects. The study team suspects that there may be a source of confounding affecting the patient’s response to the new medication. What is the most likely source of confounding in this trial?

A clinical trial is conducted to determine the effectiveness of a new drug in treating hypertension. The study compares the mean blood pressure reduction in two groups of patients: one group receives treatment A (the new drug) and the other group receives treatment B (standard therapy). The null hypothesis (H0) states there is no difference between the groups. The trial results provide enough evidence to reject H0. Which of the following conclusions is accurate?